Abstract
The UK generic market is one of the world' s largest in terms of both size and
generic penetration. This report provides sets generics into the context of
the pharmaceutical market as a whole, assesses the market outlook and provides
forecasts to 2012. It includes an insightful review of major players in the
market and detailed listing of leading products including prescription data,
price companisons and marketing authorisations. All you need to know for an
informed business judgement!
The £2.4 billion UK generics market is one of the world' s largest in
terms of both size and generic penetration. In 2005 over 59% of prescriptions
were dispensed as generics, accounting for 26% of the market value. But fierce
competition and price pressure are turning up the heat. How will the market
continue to grow?
Key areas addressed:
- 5-Year market forecast to 2012 for value
- The generics market in context of the whole pharmaceutical industry
- Pricing issues and reimbursement
- Political, legal and economic assessment
- Insightful review of 18 major domestic and foreign players in the market
- Detailed listing of 18 leading products including prescription data, price
comparisons and marketing authorisations
- Focus on developing generic markets for statins and proton pump inhibitors
The UK generics market has proved a difficult operating environment in recent
years. Many established suppliers have experienced declining sales and
profitability, due to a number of factors. On the one hand, the market is
relatively easy to enter, leading to rapid and fierce price competition for
major drugs. On the other, the UK government keeps a close watch on generic
drug pricing, and has proved willing to reduce prices for a number of products
in recent years.
As in the wider global market, there are signs of ongoing industry
consolidation. Teva and IVAX both have a strong presence in the UK, making
Teva the clear market leader since its 2006 purchase of IVAX. One new
development is the growing arrival of US companies in the market with control
of Pliva going to Barr Laboratories in 2006, and Generics (UK) set to become
part of Mylan in 2007. There are no major UK-owned generic manufacturers.
But who are the leading players and what are their strengths? What barriers to
market entry exist? What marketing authorisations have recently been issued,
and to whom? What will be the operating and regulatory environment for
companies? The answers to these and many other questions can be found in this
160-page management report Opportunities and Challenges for Generic Drugs in
the UK.
View Cart
